Already have an account? Sign in.
Guggenheim's Buy Rating for Celcuity and Gedatolisib Potential
Financial firm Guggenheim gave Celcuity a Buy rating, predicting massive sales for its breast cancer drug, Gedatolisib.
Financial firm Guggenheim gave Celcuity a Buy rating, predicting massive sales for its breast cancer drug, Gedatolisib.
Abivax shares fell after Scorpion Capital claimed its ulcerative colitis drug is toxic. The company rejected the report and reaffirmed its Phase 3 data.
CrowdStrike is reportedly in talks to acquire Zscaler in a potential $265 billion cybersecurity deal, one of the largest in the sector.
Canadian Solar shares fell sharply after a report that the solar firm and its Recurrent Energy unit are considering asset sales and a possible Chapter 11 filing.
Be the first to know when deals break, stocks move, or biotech headlines hit.